July 26th 2024
The CHMP’s positive recommendation is based on findings from the first interim analysis of the phase 3 EV-302 trial.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Hackensack Meridian Health partners with Etta.io to enhance bladder cancer detection with AI
May 12th 2023"What was great about this partnership is we recognized that this is going to be the future of medicine at some point, and we want to be able to be a part of that cutting edge technology," says Nitin K. Yerram, MD.
The role that social determinants of health play in outcomes for patients with MIBC
May 9th 2023"Proxies for social determinants of health that we found to be associated with higher overall mortality included living in a more deprived area, as well as having Medicaid or Medicare insurance," says David Miller, MD.
Oncolytic immunotherapy CG0070 plus pembrolizumab shows promise in BCG–unresponsive NMIBC
May 3rd 2023Preliminary findings from the single-arm, phase 2 CORE-001 trial showed that the combination of the oncolytic immunotherapy cretostimogene grenadenorepvec (CG0070) and pembrolizumab (Keytruda) elicited a high complete response rate in patients with BCG–unresponsive non–muscle invasive bladder cancer.
Mitomycin gel shows promise in patients with UTUC and imperative indications for therapy
May 3rd 2023“The results of the study imply that UGN-101 is not only a renal-preserving therapy for UTUC in this comorbid population, but could potentially delay the time to dialysis or radical nephroureterectomy," says Kyle M. Rose, MD.
Intravesical chemotherapy device shows promise in muscle-invasive bladder cancer
April 14th 2023"Our preliminary clinical trial found that TAR-200 was generally safe, well tolerated, and had beneficial effects on bladder cancer outcomes in a group of patients with limited treatment options," said Mark Tyson, MD, MPH.
Expert: Work needed to validate changes in diagnostic work-up for upper tract urothelial carcinoma
April 12th 2023“I think clinicians can really take away that we have more work to be done in this space of evaluating patients with microhematuria, specifically when it comes to looking at assessments of upper tract urothelial carcinoma or renal cell carcinoma,” says Jacob Taylor, MD, MPH.
Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma
April 12th 2023The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
How findings on the impact of bladder cancer treatment affect clinical decision-making
April 10th 2023"Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision," says Angela Smith, MD, MS.